|Kimball's livery for Phoenix|
Chip Ganassi Racing Teams, INDYCAR driver Charlie Kimball and Novo Nordisk, a world leader in diabetes care, w ill unveil a new livery for the No. 83 entry fielded by Novo Nordisk Chip Ganassi Racing when the car takes the track at the Phoenix Grand Prix. The car features a new black and green color scheme and carries the logo of Tresiba (insulin degludec injection), Novo Nordisk’s once-daily, long-acting basal insulin. Tresiba was approved by the U.S. Food and Drug Administration (FDA) in September 2015.1
The 2016 race season marks the eighth consecutive year of partnership between Novo Nordisk and Kimball. Since his type 1 diabetes diagnosis, Kimball has been a passionate diabetes advocate. He is the face of Novo Nordisk’s award-winning Race with Insulin campaign, which aims to raise awareness and educate the public about diabetes management.
“The new look of this car represents something very personal to me. Just as there have been advancements in racing, there have been advancements in the management of diabetes. The new look of my 2016 car represents another strong link between this program and the diabetes community," said Kimball. “I am excited about the new design, not only because of the new look, but also because it represents the next phase in my effort to educate others."
“We love the new look of Charlie’s car and are thrilled to continue our partnership with Charlie and Chip Ganassi Racing. It has been rewarding to see Charlie inspire and educate others affected by diabetes," said Camille Lee, senior vice president, Diabetes & Obesity Marketing, Novo Nordisk Inc. “We are looking forward to a great season with Charlie and the No. 83 Tresiba Chevrolet, and are extremely excited about the future of the Race with Insulin campaign."
Continue to follow Charlie’s journey and his work with Novo Nordisk at RaceWithInsulin.com, learn more about Tresiba (insulin degludec injection 200 Units/mL) at Tresiba.com, or follow Charlie on Twitter at @racewithinsulin.
Tresiba is a long-acting insulin that lasts at least 42 hours after the last of eight once-daily injections (0.4 U/kg), and has a consistently flat and stable profile at steady state.1 Tresiba is taken once daily, at any time of day. Patients who miss or are delayed in taking their dose of Tresiba should take their dose as soon as they remember, then continue with their regular dosing schedule, making sure there are at least eight hours between doses.1-3 Tresiba is available in Novo Nordisk’s insulin delivery device – FlexTouch – as a 100 units/mL or 200 units/mL pen. Tresiba U-200 FlexTouch can dose up to 160 units in a single injection. FlexTouch is also the only prefilled insulin pen with no push-button extension.1
What is Tresiba?
- Prescription Tresiba is a long-acting insulin used to control high blood sugar in adults with diabetes
- Tresiba is not for people with diabetic ketoacidosis
- Tresiba is available in 2 concentrations: 200 units/mL and 100 units/mL
- It is not known if Tresiba is safe and effective in children under 18 years of age